Loading
A phase 2 trial of Elacestrant in advanced solid tumours, run by Stemline Therapeutics, Inc., now recruiting.
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07766018 by Stemline Therapeutics, Inc., with 70 participants planned, started 2026-08-18 and due to reach its primary completion in 2028-10. Interventions recorded: Elacestrant.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Menarini / Stemline, Elacestrant, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.